Contrast Agents/Media Global Market–Forecast To 2027

Publishing Date : March, 2021
Report Code : HCPH0109
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, joints, rectally, body cavity or consumed orally. X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities.  Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney.

According to IQ4I analysis, the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.

The contrast agents/Media global market is segmented by molecule, modality, applications, route of administration, imaging, end-users and geography. Based on the molecule type, the market is segmented into Iodine based [Ionic -Monomer), Non-Ionic (Monomer and Dimer)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], Microbubble based contrast agent and others which include Barium, and iron. Among the molecules, the iodine-based contrast agents market held the largest market revenue in 2020. The Microbubble segment is expected to grow rapidly at high teen CAGR from 2020 to 2027 due to the increasing number of clinical trials for the expansion of disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share of 69.5% in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 due to the advantages of Non-ionic iodine contrast agents over ionic based contrast agents because of lower osmolality, they are better tolerated and they appear to have less toxicity. Non-Ionic Iodine-based contrasts are further segmented by their chemical structure into monomer and dimer. Monomer market accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 as they safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity. Gadolinium-based contrast agents are segmented into linear and macrocyclic based on the chemical structures. Among them, the Macrocyclic based contrast agents market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the advantages of macrocyclic over linear based contrast agents in terms of stability and less toxicity. Macrocyclic-based contrast agent further segmented into ionic and non-ionic. Among these, Non-Ionic accounted for the largest revenue in 2020. The ionic segment is growing at high single digit CAGR from 2020 to 2027.

The contrast agents market by modality is segmented into X-ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2020 and is expected grow at mid single digit CAGR from 2020 to 2027. The ultrasound segment is growing rapidly at high teen CAGR from 2020 to 2027 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of the urinary tract.

The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include the neck, liver and salivary gland imaging. The cardiovascular market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the increasing incidence and prevalence of cardiovascular diseases such as coronary heart disease, heart attack, atherosclerosis & others, increase utilization of contrast agents in coronary angiography procedures and approval contrast agents for cardiovascular indications. Cancer is the fastest-growing segment at high single digit CAGR from 2020 to 2027 due to increasing incidence and prevalence of various types of cancer, expansion of indication of contrast agents for cancer and emerging approach of development of targeted nanoparticle-based contrast agents for cancer. According to IQ4I analysis, the Contrast Agents market by route of administration is segmented into intravascular, oral, rectal and others which include (intrathecal and body cavity). Intravascular accounted for the largest share in 2020 and is the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027.

The contrast Agents market by imaging is segmented into diagnostic and interventional imaging. The diagnostic imaging market held the largest market revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027. Interventional imaging is the fastest-growing segment with low teen CAGR from 2020 to 2027 due to an increase in image guided procedures and an increase in the aging population who usually opt for minimally invasive procedures.

Based on end-user, contrast agents market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers are the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Based on the region, the contrast agent global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and Rest of the world (Turkey, Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest and fastest-growing region with revenue in 2020 by growing at high single digit CAGR from 2020 to 2027. The factors such as increasing incidence and prevalence of the chronic disease, increase in aging population, approval of contrast agents for various indications, expanding indications of contrast agents, increasing number of contrast mediated diagnostic and interventional procedures, approach for the development of novel contrast agents by the startup companies and favorable reimbursement will drive North America contrast agent market.

The contrast agents global market is consolidated. The top five players occupy major share of the market share and the remaining XX% of the market is occupied by other players. All the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agents market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
        • 2.6.7.1     PROCEDURAL VOLUME ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING DEMAND FOR DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY PROCEDURES
        • 3.3.1.2     INCREASE IN AGING POPULATION
        • 3.3.1.3     EXPANSION IN INDICATIONS OF CONTRAST MEDIA
        • 3.3.1.4     INCREASING RESEARCH ACTIVITIES TOWARDS THE DEVELOPMENT OF NOVEL CONTRAST AGENTS
        • 3.3.1.5     THE GROWTH OF MEDICAL IMAGING TECHNOLOGIES IN EMERGING MARKETS
        • 3.3.1.6     FAVORABLE REIMBURSEMENT
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECT ASSOCIATED WITH CONTRAST AGENTS
        • 3.3.2.2     SHORTAGE OF RADIOLOGISTS
        • 3.3.2.3     AVAILABILITY OF ALTERNATIVE PRODUCTS
        • 3.3.2.4     STRINGENT REGULATIONS FOR CONTRAST AGENTS
    • 3.4     REGULATORY GUIDELINES
      • 3.4.1     UNITED STATES
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     JAPAN
      • 3.4.5     SOUTH KOREA
      • 3.4.6     INDIA
    • 3.5     REIMBURSEMENT SCENARIO
      • 3.5.1     REIMBURSEMENT TABLE
    • 3.6     TECHNOLOGICAL ADVANCEMENTS
      • 3.6.1     INTRODUCTION
      • 3.6.2     ADVANCEMENTS IN COMPUTED TOMOGRAPHY TECHNOLOGY
      • 3.6.3     NANOPARTICLES BASED CONTRAST AGENTS
      • 3.6.4     MULTIMODAL CONTRAST AGENTS
      • 3.6.5     MANGANESE-BASED MRI CONTRAST AGENTS
      • 3.6.6     APPLICATION OF AI IN CONTRAST IMAGING
      • 3.6.7     BISMUTH BASED CONTRAST AGENTS
      • 3.6.8     SUPRAMOLECULAR MACROMOLECULAR ORGANIC RADICAL CONTRAST AGENT
      • 3.6.9     XENON MAGNETIC RESONANCE IMAGING
      • 3.6.10     UPCOMING TECHNOLOGIES/PRODUCTS
    • 3.7     IMPACT OF COVID-19 ON IMAGING PROCEDURES
    • 3.8     CLINICAL TRIALS
    • 3.9     SUPPLY CHAIN ANALYSIS
    • 3.10     PORTER’S FIVE FORCE ANALYSIS
      • 3.10.1     THREAT OF NEW ENTRANTS
      • 3.10.2     THREAT OF SUBSTITUTES
      • 3.10.3     BARGAINING POWER OF SUPPLIERS
      • 3.10.4     BARGAINING POWER OF BUYERS
      • 3.10.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.11     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.11.1     GLOBAL CONTRAST AGENT GLOBAL MARKET
      • 3.11.2     GLOBAL X-RAY/CT CONTRAST AGENTS MARKET
      • 3.11.3     GLOBAL MRI CONTRAST AGENTS MARKET
      • 3.11.4     GLOBAL ULTRASOUND BASED CONTRAST AGENTS MARKET
    • 3.12     COMPUTED TOMOGRAPHY MARKET – NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.12.1     GLOBAL COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.12.2     NORTH AMERICA COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.12.3     EUROPE COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.12.4     APAC COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
      • 3.12.5     ROW COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
    • 3.13     MAGNETIC RESONANCE IMAGING MARKET - PROCEDURE VOLUME, VOLUME OF CONTRAST AGENT CONSUMED & MARKET SIZE
      • 3.13.1     GLOBAL MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.13.2     NORTH AMERICA MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.13.3     EUROPE MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.13.4     APAC MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
      • 3.13.5     ROW MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
  • 4     CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE
    • 4.1     INTRODUCTION
    • 4.2     IODINE BASED CONTRAST MEDIA
      • 4.2.1     IODINE BASED IONIC CONTRAST MEDIA
      • 4.2.2     IODINE BASED NON-IONIC CONTRAST MEDIA
        • 4.2.2.1     MONOMER
        • 4.2.2.2     DIMER
    • 4.3     GADOLINIUM-BASED CONTRAST MEDIA
      • 4.3.1     MACROCYCLIC
        • 4.3.1.1     IONIC
        • 4.3.1.2     NON-IONIC
      • 4.3.2     LINEAR
        • 4.3.2.1     IONIC
        • 4.3.2.2     NON-IONIC
    • 4.4     MICROBUBBLE BASED CONTRAST MEDIA
    • 4.5     OTHER CONTRAST MEDIA
  • 5     CONTRAST AGENTS GLOBAL MARKET, BY MODALITY
    • 5.1     INTRODUCTION
    • 5.2     X-RAY/COMPUTED TOMOGRAPHY (CT)
    • 5.3     MAGNETIC RESONANCE IMAGING (MRI)
    • 5.4     ULTRASOUND
  • 6     CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     CARDIOVASCULAR
    • 6.3     CANCER
    • 6.4     GASTROINTESTINAL
    • 6.5     MUSCULOSKELETAL
    • 6.6     NEUROLOGY
    • 6.7     NEPHROLOGY
    • 6.8     OBSTETRICS AND GYNECOLOGY
    • 6.9     UROLOGY
    • 6.10     OTHERS
  • 7     CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION
    • 7.1     INTRODUCTION
    • 7.2     INTRAVASCULAR
    • 7.3     ORAL
    • 7.4     RECTAL
    • 7.5     OTHERS
  • 8     CONTRAST AGENTS GLOBAL MARKET, BY IMAGING
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSTIC IMAGING
    • 8.3     INTERVENTIONAL IMAGING
  • 9     CONTRAST AGENTS GLOBAL MARKET, BY END-USERS
    • 9.1     INTRODUCTION
    • 9.2     HOSPITAL
    • 9.3     DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
    • 9.4     OTHER END-USER
  • 10     REGIONAL ANALYSIS
    • 10.1     INTRODUCTION
    • 10.2     NORTH AMERICA
      • 10.2.1     THE U.S.
      • 10.2.2     REST OF NORTH AMERICA
    • 10.3     EUROPE
      • 10.3.1     GERMANY
      • 10.3.2     FRANCE
      • 10.3.3     THE U.K.
      • 10.3.4     REST OF EUROPE
    • 10.4     ASIA-PACIFIC
      • 10.4.1     JAPAN
      • 10.4.2     CHINA
      • 10.4.3     SOUTH KOREA
      • 10.4.4     REST OF APAC
    • 10.5     REST OF THE WORLD
      • 10.5.1     TURKEY
      • 10.5.2     BRAZIL
      • 10.5.3     LATAM AND MIDDLE EAST & AFRICA
  • 11     COMPETITIVE LANDSCAPE
    • 11.1     INTRODUCTION
    • 11.2     APPROVALS
    • 11.3     AGREEMENT
    • 11.4     ACQUISITION
  • 12     MAJOR PLAYER PROFILES
    • 12.1     BAYER GROUP
      • 12.1.1     OVERVIEW
      • 12.1.2     FINANCIALS
      • 12.1.3     PRODUCT PORTFOLIO
      • 12.1.4     KEY DEVELOPMENTS
      • 12.1.5     BUSINESS STRATEGY
      • 12.1.6     SWOT ANALYSIS
    • 12.2     BEIJING BEILU PHARMACEUTICAL CO., LTD
      • 12.2.1     OVERVIEW
      • 12.2.2     FINANCIALS
      • 12.2.3     PRODUCT PORTFOLIO
      • 12.2.4     KEY DEVELOPMENTS
      • 12.2.5     BUSINESS STRATEGY
      • 12.2.6     SWOT ANALYSIS
    • 12.3     BRACCO GROUP
      • 12.3.1     OVERVIEW
      • 12.3.2     FINANCIALS
      • 12.3.3     PRODUCT PORTFOLIO
      • 12.3.4     KEY DEVELOPMENTS
      • 12.3.5     BUSINESS STRATEGY
      • 12.3.6     SWOT ANALYSIS
    • 12.4     DONGKOOK LIFE SCIENCE
      • 12.4.1     OVERVIEW
      • 12.4.2     FINANCIALS
      • 12.4.3     PRODUCT PORTFOLIO
      • 12.4.4     KEY DEVELOPMENTS
      • 12.4.5     BUSINESS STRATEGY
      • 12.4.6     SWOT ANALYSIS
    • 12.5     FUJIPHARMA CO LTD
      • 12.5.1     OVERVIEW
      • 12.5.2     FINANCIALS
      • 12.5.3     PRODUCT PORTFOLIO
      • 12.5.4     KEY DEVELOPMENTS
      • 12.5.5     BUSINESS STRATEGY
      • 12.5.6     SWOT ANALYSIS
    • 12.6     GE COMPANY (GE HEALTHCARE)
      • 12.6.1     OVERVIEW
      • 12.6.2     FINANCIALS
      • 12.6.3     PRODUCT PORTFOLIO
      • 12.6.4     KEY DEVELOPMENTS
      • 12.6.5     BUSINESS STRATEGY
      • 12.6.6     SWOT ANALYSIS
    • 12.7     GUERBET
      • 12.7.1     OVERVIEW
      • 12.7.2     FINANCIALS
      • 12.7.3     PRODUCT PORTFOLIO
      • 12.7.4     KEY DEVELOPMENTS
      • 12.7.5     BUSINESS STRATEGY
      • 12.7.6     SWOT ANALYSIS
    • 12.8     LANTHEUS MEDICAL IMAGING INC.
      • 12.8.1     OVERVIEW
      • 12.8.2     FINANCIALS
      • 12.8.3     PRODUCT PORTFOLIO
      • 12.8.4     KEY DEVELOPMENTS
      • 12.8.5     BUSINESS STRATEGY
      • 12.8.6     SWOT ANALYSIS
    • 12.9     SANOCHEMIA PHARMACEUTICAL AG
      • 12.9.1     OVERVIEW
      • 12.9.2     FINANCIALS
      • 12.9.3     PRODUCT PORTFOLIO
      • 12.9.4     KEY DEVELOPMENTS
      • 12.9.5     BUSINESS STRATEGY
      • 12.9.6     SWOT ANALYSIS
    • 12.10     TAEJOON PHARM CO., LTD
      • 12.10.1     OVERVIEW
      • 12.10.2     FINANCIALS
      • 12.10.3     PRODUCT PORTFOLIO
      • 12.10.4     KEY DEVELOPMENTS
      • 12.10.5     BUSINESS STRATEGY
      • 12.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 2     X-RAY/ CT CONTRAST AGENT MEDIATED GLOBAL PROCEDURE VOLUME, (2019-2027) (MN)
      • TABLE 3     X-RAY/ CT CONTRAST AGENT GLOBAL CONSUMPTION, (2019-2027) (MN L)
      • TABLE 4     MRI CONTRAST AGENT CONTRAST MEDIATED GLOBAL PROCEDURE VOLUME, (2019-2027) (MN)
      • TABLE 5     MRI CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2027) (MN L)
      • TABLE 6     ULTRASOUND CONTRAST AGENTS MEDIATED PROCEDURE VOLUME, (2020-2027) (MN)
      • TABLE 7     ULTRASOUND CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2027) (L)
      • TABLE 8     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MOLECULE, (2019-2027) ($MN)
      • TABLE 9     IODINE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2019-2027) ($MN)
      • TABLE 10     IODINE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
      • TABLE 11     IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
      • TABLE 12     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2020-2027) ($MN)
      • TABLE 13     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
      • TABLE 14     IODINE BASED NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
      • TABLE 15     IODINE BASED NON-IONIC DIMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2027) ($MN)
      • TABLE 16     GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2020-2027) ($MN)
      • TABLE 17     GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2019 -2027)($MN)
      • TABLE 19     MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 20     MACROCYCLIC IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 21     MACROCYCLIC NON-IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 22     LINEAR GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 23     LINEAR GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 24     LINEAR IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 25     LINEAR NON-IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 26     MICROBUBBLE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 27     OTHER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 28     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MODALITY, (2019-2027)($MN)
      • TABLE 29     X-RAY/CT GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 30     MAGNETIC RESONANCE IMAGING GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 31     ULTRASOUND GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 32     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027)($MN)
      • TABLE 33     CARDIOVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 34     CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 35     GASTROINTESTINAL GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 36     MUSCULOSKELETAL GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 37     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 38     NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 39     OBSTETRICS AND GYNECOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 40     UROLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 41     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 42     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027)($MN)
      • TABLE 43     INTRAVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 44     ORAL GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 45     RECTAL GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 46     OTHER GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 47     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IMAGING, (2019-2027)($MN)
      • TABLE 48     DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 49     INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 50     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY END-USERS, (2019-2027)($MN)
      • TABLE 51     HOSPITAL GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 52     DIAGNOSTIC & AMBULATORY SURGICAL CENTER GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 53     OTHER END-USERS CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 54     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027)($MN)
      • TABLE 55     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2019-2027)($MN)
      • TABLE 56     NORTH AMERICA IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 57     NORTH AMERICA IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 58     NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 59     NORTH AMERICA MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 60     NORTH AMERICA LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 61     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2019-2027)($MN)
      • TABLE 62     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2019-2027)($MN)
      • TABLE 63     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027)($MN)
      • TABLE 64     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2019-2027)($MN)
      • TABLE 65     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2019-2027)($MN)
      • TABLE 66     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY COUNTRY, (2019-2027)($MN)
      • TABLE 67     EUROPE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2019-2027)($MN)
      • TABLE 68     EUROPE IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 69     EUROPE IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 70     EUROPE GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 71     EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 72     EUROPE LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 73     EUROPE CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2019-2027)($MN)
      • TABLE 74     EUROPE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2019-2027)($MN)
      • TABLE 75     EUROPE CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027)($MN)
      • TABLE 76     EUROPE CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2019-2027)($MN)
      • TABLE 77     EUROPE CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2019-2027)($MN)
      • TABLE 78     EUROPE CONTRAST AGENTS MARKET REVENUE, BY COUNTRY, (2019-2027)($MN)
      • TABLE 79     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2019-2027)($MN)
      • TABLE 80     ASIA-PACIFIC IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 81     ASIA-PACIFIC IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 82     ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 83     ASIA-PACIFIC MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 84     ASIA-PACIFIC LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 85     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2019-2027)($MN)
      • TABLE 86     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2019-2027)($MN)
      • TABLE 87     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027)($MN)
      • TABLE 88     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2019-2027)($MN)
      • TABLE 89     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2019-2027)($MN)
      • TABLE 90     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY COUNTRY, (2019-2027)($MN)
      • TABLE 91     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2019-2027)($MN)
      • TABLE 92     REST OF THE WORLD IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 93     REST OF THE WORLD IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 94     REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2019-2027)($MN)
      • TABLE 95     REST OF THE WORLD MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 96     REST OF THE WORLD LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2019-2027)($MN)
      • TABLE 97     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2019-2027)($MN)
      • TABLE 98     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2019-2027)($MN)
      • TABLE 99     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2019-2027)($MN)
      • TABLE 100     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2019-2027)($MN)
      • TABLE 101     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2019-2027)($MN)
      • TABLE 102     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY COUNTRY, (2019-2027)($MN)
      • TABLE 103     APPROVALS (2019-2020)
      • TABLE 104     AGREEMENT, (2019-2020)
      • TABLE 105     ACQUISITION, (2019-2020)
      • TABLE 106     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2018-2020) (Q3) ($MN)
      • TABLE 107     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2018-2020) (Q3) ($MN)
      • TABLE 108     BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) (Q3) ($MN)
      • TABLE 109     FUJIPHARMA CO LTD: TOTAL REVENUE AND R&D EXPENSES, (2019–2021) (Q1) ($MN)
      • TABLE 110     FUJIPHARMA CO LTD: TOTAL REVENUE, BY THERAPEUTIC CATEGORY (2019-2021) (Q1) ($MN)
      • TABLE 111     GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2018 – 2020) ($MN)
      • TABLE 112     GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2018-2020) ($MN)
      • TABLE 113     GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2018 –2020) ($MN)
      • TABLE 114     GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 115     GUERBET TOTAL REVENUE, BY SEGMENT (2018-2020) (Q3) ($MN)
      • TABLE 116     GUERBET TOTAL REVENUE, BY GEOGRAPHIC (2018-2020) (Q3) ($MN)
      • TABLE 117     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q3) ($MN)
      • TABLE 118     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2018-2020) (Q3) ($MN)
      • TABLE 119     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) (Q3)

      LIST OF FIGURES

      • FIGURE 1     CONTRAST AGENTS GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2019-2027) ($MN), 2020 (%)
      • FIGURE 2     RESEARCH METHODOLOGY: CONTRAST AGENTS GLOBAL MARKET
      • FIGURE 3     CONTRAST AGENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     CONTRAST AGENTS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     CONTRAST AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     CONTRAST AGENTS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     CLINICAL TRIALS BY MODALITY
      • FIGURE 9     CLINICAL TRIALS BY APPLICATION AND PHASE
      • FIGURE 10     CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     CONTRAST AGENT MARKET: PORTER’S ANALYSIS
      • FIGURE 12     GLOBAL CONTRAST AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 13     GLOBAL X-RAY/CT CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS (2020) (%)
      • FIGURE 14     GLOBAL MRI CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS (2020) (%)
      • FIGURE 15     GLOBAL ULTRASOUND BASED CONTRAST AGENTS: MAJOR PLAYER ANALYSIS (2020) (%)
      • FIGURE 16     REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED X-RAY/CT PROCEDURE VOLUME : (2020) (NO’S)
      • FIGURE 17     GLOBAL CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE (2020) ($MN)
      • FIGURE 18     NORTH AMERICA CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 19     EUROPE CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 20     ASIA – PACIFIC CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 21     ROW CT/ X-RAY PENETRATION, NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 22     REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED MRI PROCEDURE VOLUME : (2020) (NO’S)
      • FIGURE 23     GLOBAL MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 24     NORTH AMERICA MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 25     EUROPE MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED MARKET SIZE, (2020) ($MN)
      • FIGURE 26     ASIA – PACIFIC MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 27     ROW MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($ MN)
      • FIGURE 28     REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED ULTRASOUND IMAGING PROCEDURE VOLUME: (2020) (NO’S)
      • FIGURE 29     CONTRAST AGENTS GLOBAL MARKET SHARE, BY MOLECULE (2020 V/S 2027) (%)
      • FIGURE 30     GLOBAL IODINE BASED CONTRAST AGENTS MARKET REVENUE BY IONICITY AND NON-IONIC CONTRAST AGENTS BY CHEMICAL STRUCTURE (2020) ($MN)
      • FIGURE 31     IODINE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 32     IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%)
      • FIGURE 33     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 34     IODINE BASED NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 35     MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY IONICITY (2020 V/S 2027) (%)
      • FIGURE 36     MACROCYCLIC IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 37     OTHER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 38     CONTRAST AGENTS GLOBAL MARKET SHARE, BY MODALITY (2020 VS 2027) (%)
      • FIGURE 39     X-RAY/CT GLOBAL MARKET REVENUE, BY REGION (2020 VS 2027) (%)
      • FIGURE 40     CONTRAST AGENTS GLOBAL MARKET SHARE, BY APPLICATION (2020) (%)
      • FIGURE 41     CARDIOVASCULAR GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 42     CANCER GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 43     GASTROINTESTINAL GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 44     MUSCULOSKELETAL GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 45     NEPHROLOGY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 46     OBSTETRICS AND GYNECOLOGY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 47     UROLOGY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 48     OTHER APPLICATIONS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 49     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2020) ($MN)
      • FIGURE 50     INTRAVASCULAR GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 51     ORAL GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 52     RECTAL GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 53     OTHER GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 54     CONTRAST AGENTS GLOBAL MARKET SHARE, BY IMAGING (2020 V/S 2027) (%)
      • FIGURE 55     DIAGNOSTIC IMAGING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
      • FIGURE 56     CONTRAST AGENTS GLOBAL MARKET SHARE, BY END-USERS, (2020 V/S 2027) (%)
      • FIGURE 57     HOSPITAL GLOBAL MARKET SHARE, BY END-USERS, (2020 V/S 2027) (%)
      • FIGURE 58     OTHER END-USER GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 59     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 60     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY (2020) ($ MN)
      • FIGURE 61     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY MOLECULE (2020 V/S 2027) (%)
      • FIGURE 62     NORTH AMERICA IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY AND CHEMICAL STRUCTURE, (2020) ($MN)
      • FIGURE 63     NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2020 V/S 2027) (%)
      • FIGURE 64     NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY IONOCITY, (2020 V/S 2027) (%)
      • FIGURE 65     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY MODALITY, (2020 VS 2027) (%)
      • FIGURE 66     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY APPLICATION, (2020) (%)
      • FIGURE 67     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION, (2020 VS 2027) (%)
      • FIGURE 68     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2020 VS 2027) (%)
      • FIGURE 69     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY END-USER, (2020 VS 2027) (%)
      • FIGURE 70     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 71     U.S. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 72     U.S. CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 73     U.S. CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 74      REST OF NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 75     REST OF NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 76     REST NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 77     EUROPE CONTRAST AGENTS MARKET SHARE, BY MOLECULE (2020 V/S 2027) (%)
      • FIGURE 78     EUROPE IODINE BASED CONTRAST AGENTS REVENUE, BY IONICITY AND BY CHEMICAL STRUCTURE, (2020) ($MN)
      • FIGURE 79     EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2020 VS 2027) (%)
      • FIGURE 80     EUROPE GADOLINIUM MACROCYCLIC BASED CONTRAST AGENTS MARKET SHARE, BY IONICITY, (2020 VS 2027) (%)
      • FIGURE 81     EUROPE CONTRAST AGENTS MARKET SHARE, BY MODALITY, (2020 V/S 2027) (%)
      • FIGURE 82     EUROPE CONTRAST AGENTS MARKET SHARE, BY APPLICATION, (2020) (%)
      • FIGURE 83     EUROPE CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
      • FIGURE 84     EUROPE CONTRAST AGENTS MARKET SHARE, BY IMAGING (2020 V/S 2027) (%)
      • FIGURE 85     EUROPE CONTRAST AGENTS MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 86     EUROPE CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 87     GERMANY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 88     GERMANY CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 89     GERMANY CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 90     FRANCE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 91     FRANCE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 92      FRANCE CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 93     U.K. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 94     U.K. CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 95     U.K. CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 96     REST OF EUROPE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 97     REST OF EUROPE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 98     REST OF EUROPE CONTRAST AGENTS MARKET REVENUE, BY IMAGING, AND BY END –USER (2020 V/S 2027) ($MN)
      • FIGURE 99     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY MOLECULE (2020 V/S 2027) (%)
      • FIGURE 100     ASIA-PACIFIC IODINE BASED CONTRAST AGENTS MARKET SHARE BY IONICITY AND CHEMICAL STRUCTURE, (2020) ($MN)
      • FIGURE 101     ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2020 V/S 2027) (%)
      • FIGURE 102     ASIA-PACIFIC MACROCYCLIC - BASED CONTRAST AGENTS MARKET SHARE, BY IONOCITY, (2020 V/S 2027) (%)
      • FIGURE 103     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY MODALITY, (2020 V/S 2027) (%)
      • FIGURE 104     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY APPLICATION, (2020) ($MN)
      • FIGURE 105     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%)
      • FIGURE 106     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY IMAGING (2020 V/S 2027) (%)
      • FIGURE 107     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 108     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 109     JAPANCONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 110     JAPAN CONTRAST AGENTS MARKET REVENUE,BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 111     JAPAN CONTRAST AGENTS MARKET REVENUE BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 112     CHINACONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 113     CHINA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 114     CHINA CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 115     SOUTH KOREACONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 116     SOUTH KOREA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 117     SOUTH KOREA CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 118     REST OF APAC CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 119     REST OF APAC CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 120     REST OF APAC CONTRAST AGENTS MARKET REVENUE CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 121     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY MOLECULE (2020 V/S 2027) (%)
      • FIGURE 122     REST OF THE WORLD IODINE BASED CONTRAST AGENT MARKET REVENUE BY IONICITY AND BY CHEMICAL STRUCTURE, (2020) ($MN)
      • FIGURE 123     REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2020 V/S 2027) (%)
      • FIGURE 124     REST OF THE WORLD MACROCYCLIC BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE (2020 V/S 2027) (%)
      • FIGURE 125     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY MODALITY, (2020 VS 2027) (%)
      • FIGURE 126     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2020) ($MN)
      • FIGURE 127     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION, (2020 VS 2027) (%)
      • FIGURE 128     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2020 VS 2027) (%)
      • FIGURE 129     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY END-USER, (2020 VS 2027) (%)
      • FIGURE 130     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 131     TURKEY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 132     TURKEY CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 133     TURKEY CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 134     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 135     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 136     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY IMAGING, AND BY END-USER (2020 V/S 2027) ($MN)
      • FIGURE 137     LATAM AND MIDDLE EAST & AFRICA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 138     LATAM AND MIDDLE EAST & AFRICA CONTRAST AGENT MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN)
      • FIGURE 139     LATAM AND MIDDLE EAST & AFRICA CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 140     KEY GROWTH STRATEGIES (2019 – 2020)
      • FIGURE 141     SWOT: BAYER GROUP
      • FIGURE 142     SWOT: BEIJING BEILU PHARMACEUTICAL CO., LTD.
      • FIGURE 143     SWOT: BRACCO GROUP
      • FIGURE 144     SWOT: DONGKOOK LIFE SCIENCE
      • FIGURE 145     SWOT: FUJIPHARMA CO LTD
      • FIGURE 146     SWOT: GE HEALTHCARE
      • FIGURE 147     SWOT: GUERBET
      • FIGURE 148     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 149     SWOT: SANOCHEMIA PHARMACEUTICAL AG
      • FIGURE 150     SWOT: TAEJOON PHARM CO., LTD.

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ASCELIA PHARMA AB
      • 2     BAYER GROUP
      • 3     BEIJING BEILU PHARMACEUTICALS COMPANY LIMITED
      • 4     BIEM İLAÇ SAN. AND TIC, INC.
      • 5     BRACCO GROUP
      • 6     DAIHAN PHARM. CO. LTD.
      • 7     DONGKOOK LIFESCIENCE
      • 8     ESKAY FINE CHEMICALS
      • 9     FERRIC CONTRAST COMPANY
      • 10     FUJIFILM HOLDING CORPORATION
      • 11     FUJIPHARMA CO. LTD
      • 12     GE COMPANY (GE HEALTHCARE)
      • 13     GENUS MEDICAL TECHNOLOGIES
      • 14     GUERBET
      • 15     IMAGION BIOSYSTEMS, LTD
      • 16     IMAX DIAGNOSTIC IMAGING LIMITED
      • 17     INLIGHTA BIOSCIENCES, LLC
      • 18     JB CHEMICALS AND PHARMACEUTICALS LTD
      • 19     JODAS EXPOIM PVT. LTD
      • 20     LANTHEUS MEDICAL IMAGING
      • 21     MAGNUS HEALTH
      • 22     NANOLOGY LABS INC
      • 23     NANO-THERAPEUTICS
      • 24     OTSUKA PHARMACEUTICAL CO. LTD. (INTERPHARMA PRAHA)
      • 25     REGE IMAGING & CINEFILMS PRIVATE LIMITED
      • 26     REVEAL PHARMACEUTICALS
      • 27     SANOCHEMIA PHARMAZEUTIKA AG
      • 28     SPAGO NANOMEDICAL
      • 29     STELLENCE PHARMSCIENCE PRIVATE LIMITED
      • 30     TAEJOON PHARM CO. LTD.,
      • 31     TRIVITRON HEALTHCARE
      • 32     TRUST BIOSONICS
      • 33     UNIJULES LIFE SCIENCES LTD
      • 34     UNIMARK REMEDIES
      • 35     VB TECHNOCHEMICALS SA
      • 36     ZHEJIANG STARRY PHARMA